deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT02836847

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Cholangiocarcinoma of the Extrahepatic Bile Duct Gallbladder Cancer
Interventions Cetuximab Crizotinib Everolimus GEMOX Gefitinib Lapatinib Sorafenib Trastuzumab biological test
Updated 5 times since 2017 Last updated: May 4, 2018 Started: Jul 31, 2016 Primary completion: Dec 31, 2019 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02836847, this PHASE2 trial focuses on Cholangiocarcinoma of the Extrahepatic Bile Duct and Gallbladder Cancer and remains ongoing. Sponsored by Eastern Hepatobiliary Surgery Hospital, it has been updated 5 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotRecruiting~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 23 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Jun 2018 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Hepatobiliary Surgery Hospital
  • Huashan Hospital
  • RenJi Hospital
  • Ruijin Hospital
  • Shanghai Jiao Tong University School of Medicine
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Data source: Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations